MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock-At The...
$14,385K
Net cash provided by
financing activities
$6,771K
Canceled cashflow
$7,614K
Net decrease in cash
and cash...
-$1,378K
Canceled cashflow
$6,771K
Stock-based compensation
expense
$1,788K
Accounts payable
$730K
Value of shares issued
to consultants
$657K
Non-cash lease expense
$71K
Depreciation of property and
equipment
$15K
Unrealized foreign
exchange loss
-$7K
something is missing
-$7,614K
Net cash used in
operating activities
-$8,138K
Canceled cashflow
$3,268K
Effect of exchange rate
changes on cash and cash...
-$11K
Net loss
-$9,442K
Accrued liabilities
-$894K
Prepaid expenses
$742K
Other receivables
$253K
Operating lease
liabilities
-$75K
Back
Back
Cash Flow
ONCOLYTICS BIOTECH INC (ONCY)
ONCOLYTICS BIOTECH INC (ONCY)
source: myfinsight.com